Home
Search

Letters, Testimony & Comments

BIO submits letters, testimony, and comments to government and regulatory bodies throughout the United States and around the world.

Featured Letters, Testimony, & Comments
BIO Letter to HRSA on 340B Rebate Model
Under the 340B program, participating manufacturers must offer 340B pricing on their covered outpatient drugs by covered entities, as a condition of having those drugs federally payable under Medicare Part B and Medicaid. Critically, Congress…
Learn more
CSBA Letter to Congressional Leadership on…
Learn more
BIO Comments to the USPTO’s MAY 10, 2024 Proposed…
BIO submitted these comments in response to the United States Patent and Trademark Office’s May 10, 2024, Notice of Proposed Rulemaking regarding Terminal Disclaimer Practice to Obviate Nonstatutory Double Patenting.
Learn more
All Letters, Testimony & Comments
  • Show All
Search
Results
BIO Joins Coalition Letter to Biden Administration Supporting SAF Tax Credit
April 2, 2021
Dear Secretary Buttigieg, National Climate Advisor McCarthy, and Director Deese: The undersigned organizations, representing aviation industry stakeholders including passenger and cargo carriers, business and general aviation, aircraft and engine…
BIO Comments on FDA’s Public Meeting Announcement: Best Practices for Development and Application of Disease Progression Models
March 26, 2021
On Friday, March 26th, BIO submitted comments on the U.S. Food and Drug Administration (FDA)’s public meeting announcement titled, “Best Practices for Development and Application of Disease Progression Models.” BIO appreciates that FDA is seeking…
BIO letter to the Senate Judiciary Committee in support of the Inventor Diversity for Economic Advancement Act of 2021 (IDEA Act)
March 26, 2021
The Biotechnology Innovation Organization is delighted to support the Inventor Diversity for Economic Advancement Act of 2021 and urge swift enactment of this important measure.
BIO Submits Testimony to House Science Subcommittee Hearing on Sustainable Aviation Fuels
March 24, 2021
The Biotechnology Innovation Organization is pleased to submit a statement for the record to the United States House of Representatives Committee on Science and Technology and Space and Aeronautics Subcommittee hearing entitled, "Examining R&D…
BIO Letter to New Mexico Governor on Clean Fuel Standard in Special Session
March 22, 2021
I write today on behalf of the Biotechnology Industry Organization (BIO) – the world’s largest biotechnology trade group – to urge you to put Senate Bill 11 – the New Mexico Clean Fuel Standard Act – on the agenda for the March 31 special session of…
BIO Testimony to House Energy and Commerce Subcommittee Hearing on the CLEAN Future Act
March 18, 2021
The Biotechnology Innovation Organization (BIO) is pleased to submit a statement for the record to the United States House of Representatives Committee on Energy and Commerce Subcommittee on Environment and Climate Change hearing entitled, "The…
BIO Letter to DEFRA Consultation on the Regulation of Genetic Technologies
March 17, 2021
The Biotechnology Innovation Organization (BIO) welcomes the United Kingdom’s (UK) consultation on the application of genome editing in the breeding of plants and animals.  The UK has the unique opportunity to be the first country within Europe…
BIO Submits Testimony to Senate Agriculture Committee's First Climate Hearing in 2021
March 11, 2021
The Biotechnology Innovation Organization (BIO) is pleased to submit a statement for the record to the United States Senate Committee on Agriculture, Nutrition, and Forestry hearing entitled, “Farmers and Foresters: Opportunities to Lead in Tackling…
BIO Statement to House Ag Hearing on Food Insecurity
March 11, 2021
The Biotechnology Innovation Organization is pleased to submit a statement for the record to the United States House of Representatives Committee on Agriculture hearing entitled, "A Look at Food Insecurity in America." The Committee's hearing…
BIO Sends Letter to President Biden Discussing Collaboration to Ensure Patient Access to COVID Treatments
March 8, 2021
BIO President and CEO Dr. Michelle McMurry-Heath sent President Biden a letter sharing thoughts on how to best work together with global partners to ensure that patients around the world get access to COVID vaccines, therapeutics, and…